WALTHAM, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the publication of results from a 26-patient, Phase 2 study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC) in the current issue of the journal THYROID. The authors of the study, titled “A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome” (Mooney et al, Vol. 19, Num.3, 2009), concluded that fosbretabulin, administered as a single agent to ATC patients who had progressed or relapsed following initial therapy, appeared to be well-tolerated with encouraging survival results that provide a strong rationale for the ongoing Phase 2/3 pivotal registration study with fosbretabulin in ATC (FACT trial).
